(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 201.56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Absci's revenue in 2026 is $2,815,000.On average, 10 Wall Street analysts forecast ABSI's revenue for 2026 to be $3,118,104,067, with the lowest ABSI revenue forecast at $442,092,301, and the highest ABSI revenue forecast at $8,863,649,895. On average, 9 Wall Street analysts forecast ABSI's revenue for 2027 to be $5,338,790,837, with the lowest ABSI revenue forecast at $442,092,301, and the highest ABSI revenue forecast at $16,044,642,358.
In 2028, ABSI is forecast to generate $13,094,804,034 in revenue, with the lowest revenue forecast at $668,100,712 and the highest revenue forecast at $25,829,317,880.